Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 25, 2026

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

View original at globenewswire.com
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2020 ASCO guidelines recommend no specific pharmacological intervention as standard of care for cancer anorexia cachexia

    60% confidence

  • There is no FDA-approved pharmacological treatment for cancer anorexia cachexia

    60% confidence

  • Following positive Phase 2 results and coverage by UK and USA media outlets, Artelo has received multiple expressions of potential collaboration interest from global and regional pharmaceutical companies

    60% confidence

  • The collaboration with Queen's University Belfast and partners broadens ART27.13's therapeutic profile beyond cancer-related anorexia while preserving internal focus on the lead indication

    60% confidence

  • ART12.11 showed antidepressant-like activity on par with sertraline with improved cognitive benefits in preclinical models

    60% confidence

  • ART26.12 showed sustained analgesic effects without development of tolerance in osteoarthritis pain model, matching naproxen in efficacy

    60% confidence

  • Artelo is not a one-trick biotech but a platform play in one of medicine's most underserved mechanistic categories

    60% confidence

  • ART27.13's 6.4% weight gain versus 5.4% weight loss in placebo represents a clinically meaningful signal in cancer anorexia cachexia

    60% confidence

Cited in these Via News reports